Business Description
Poseida Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US73730P1084
Share Class Description:
PSTX: Ordinary SharesDescription
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.79 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.95 | |||||
| Debt-to-EBITDA | -1.79 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.29 | |||||
| Beneish M-Score | -1.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 29.4 | |||||
| 3-Year EPS without NRI Growth Rate | 27.6 | |||||
| 3-Year FCF Growth Rate | 33.7 | |||||
| 3-Year Book Growth Rate | -36.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | -35.97 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 96.06 | |||||
| 9-Day RSI | 92.81 | |||||
| 14-Day RSI | 90 | |||||
| 6-1 Month Momentum % | -18.86 | |||||
| 12-1 Month Momentum % | -11.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | |||||
| Quick Ratio | 3.2 | |||||
| Cash Ratio | 2.95 | |||||
| Days Sales Outstanding | 27.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.6 | |||||
| Shareholder Yield % | 0.37 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -41.43 | |||||
| Net Margin % | -40.28 | |||||
| FCF Margin % | -11.35 | |||||
| ROE % | -66.04 | |||||
| ROA % | -21.23 | |||||
| ROIC % | -61.75 | |||||
| ROC (Joel Greenblatt) % | -131.01 | |||||
| ROCE % | -25.38 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.82 | |||||
| PB Ratio | 10.37 | |||||
| Price-to-Tangible-Book | 11.11 | |||||
| EV-to-EBIT | -14.83 | |||||
| EV-to-EBITDA | -16.6 | |||||
| EV-to-Revenue | 5.08 | |||||
| EV-to-Forward-Revenue | 20.52 | |||||
| EV-to-FCF | -44.73 | |||||
| Price-to-Net-Current-Asset-Value | 20.28 | |||||
| Price-to-Net-Cash | 37.32 | |||||
| Earnings Yield (Greenblatt) % | -6.74 | |||||
| FCF Yield % | -1.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PSTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Poseida Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 150.858 | ||
| EPS (TTM) ($) | -0.62 | ||
| Beta | 0.88 | ||
| Volatility % | 69.51 | ||
| 14-Day RSI | 90 | ||
| 14-Day ATR ($) | 0.657011 | ||
| 20-Day SMA ($) | 3.532 | ||
| 12-1 Month Momentum % | -11.72 | ||
| 52-Week Range ($) | 1.87 - 9.42 | ||
| Shares Outstanding (Mil) | 97.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Poseida Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Poseida Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Poseida Therapeutics Inc Frequently Asked Questions
What is Poseida Therapeutics Inc(PSTX)'s stock price today?
The current price of PSTX is $9.33. The 52 week high of PSTX is $9.42 and 52 week low is $1.87.
When is next earnings date of Poseida Therapeutics Inc(PSTX)?
The next earnings date of Poseida Therapeutics Inc(PSTX) is 2025-03-07 Est..
Does Poseida Therapeutics Inc(PSTX) pay dividends? If so, how much?
Poseida Therapeutics Inc(PSTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers